MDGL - Madrigal Pharmaceuticals GAAP EPS of -$7.38 misses by $1.18
2024-05-07 07:04:22 ET
More on Madrigal Pharmaceuticals
- Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
- Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
- Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead
- Madrigal announces US launch of NASH/MASH drug Rezdiffra
- Madrigal Pharmaceuticals commences underwritten public offering